Congress Fiddles While Reimportation Issue Burns
Several drug re-importation bills are currently being considered in Congress.
Becoming Woman Wise: Marketing Healthcare to Women
Women account for more than half of the population in the United States and it makes absolute sense to market to women where, when, and how they choose.
Accelerating Your Multicultural Communications
Multicultural communications can be a powerful addition to the armamentarium of the healthcare marketer.
How Cheap are Canada’s Drugs Really?
This article compares pharmaceutical prices paid by governments in the United States and Canada.
OpEd: Drug Importation Crisis: Terror Politics to the Rescue!
The FDA just played the terrorist trump card in its battle against the legalization of the reimportation of drugs.
Pharma Marketing News Vol. 3, #7 (July/August 2004) Archive
Dear Reader, Welcome to the archive of the July/August, 2004 issue Pharma Marketing News. Vol. 3, No. 7: July/August 2004 - CONTENTS...
Pharma Marketing News Vol. 3, #7 (July/August 2004) Executive Summary
Dear Reader: Welcome to the executive summary of the July/August, 2004 issue of Pharma Marketing News. This edition offers you reprints from the current issue...
Pharma Marketing News Vol. 3, #8 (September 2004) Executive Summary
Dear Reader: Welcome to the executive summary of the July/August, 2004 issue of Pharma Marketing News. This edition offers you reprints from the current issue...
California’s Physician Prescribing Act: A History of Twists and Turns
This article traces the changes in California's Physician Prescribing Act (AB 262) as it wended its way through various committees. It describes the provisions that may limit the use of physician prescribing data by pharmaceutical marketers, identifies organizations that have taken a position in favor and against the bill, and discusses the arguments on both sides of the issue.
A Crisis in Professional Detailing
Two physicians -- one a specialist (cardiologist) and one a primary care physician -- offered their insights on how pharmaceutical companies can improve their relationships with physicians.
